Tag: Sequel Med Tech
Sequel Med Tech’s twiist now available nationwide
March 10, 2026HME News Staff
MANCHESTER, N.H. – Sequel Med Tech has announced broad national availability of its twist Automated Insulin Delivery (AID) System powered by Tidepool, following clearance by the U.S. Food and Drug Administration in 2024 and a subsequent controlled launch. “With twiist now accessible to more people than ever before, we’ve reached a meaningful milestone for Sequel and for people living with type 1 diabetes,” said Sequel CEO and Co-Founder Alan Lotvin, MD. “twiist was built...
Arecor, Sequel partner to advance diabetes treatment through clinical trials and beyond
September 29, 2025HME News Staff
CAMBRIDGE, U.K. - Arecor Therapeutics, a biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, has signed a co-development agreement with Sequel Med Tech, a company that is developing insulin delivery technologies. Part of the agreement:
Combining Arecor’s AT278 (500U/ml) with Sequel’s twiist automated insulin deliver (AID) system powered by Tidepool; and
Implementing a royalty financing agreement with Ligand...
Sequel Med Tech collaborates with Abbott
March 19, 2025HME News Staff
MANCHESTER, N.H. – Sequel Med Tech has announced that Abbott’s FreeStyle Libre 3 Plus sensor will be the first continuous glucose monitoring device to work with its twiist Automated Insulin Delivery (AID) System powered by Tidepool. The sensor will be compatible with twiist when the system is expected to launch in the second quarter of 2025. “We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology as our first CGM partner,...